Clear Street’s NeuroSense Therapeutics Warrant NRSNW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.97K | Sell |
63,085
-300
| -0.5% | -$43 | ﹤0.01% | 1280 |
|
|
2026
Q1 | $12.7K | Hold |
63,385
| – | – | ﹤0.01% | 933 |
|
|
2025
Q4 | $20.3K | Sell |
63,385
-300
| -0.5% | -$107 | ﹤0.01% | 718 |
|
|
2025
Q3 | $24.2K | Hold |
63,685
| – | – | ﹤0.01% | 616 |
|
|
2025
Q2 | $40.4K | Sell |
63,685
-2,074
| -3% | -$809 | ﹤0.01% | 376 |
|
|
2025
Q1 | $13.5K | Buy |
65,759
+100
| +0.2% | +$26 | ﹤0.01% | 344 |
|
|
2024
Q4 | $28.9K | Sell |
65,659
-100
| -0.2% | -$27 | ﹤0.01% | 233 |
|
|
2024
Q3 | $9.87K | Buy |
65,759
+6,487
| +11% | +$1.1K | ﹤0.01% | 388 |
|
|
2024
Q2 | $12.2K | Buy |
59,272
+100
| +0.2% | +$23 | ﹤0.01% | 408 |
|
|
2024
Q1 | $24.9K | Sell |
59,172
-100
| -0.2% | -$25 | ﹤0.01% | 283 |
|
|
2023
Q4 | $4.63K | Hold |
59,272
| – | – | ﹤0.01% | 459 |
|
|
2023
Q3 | $9.18K | Buy |
59,272
+600
| +1% | +$109 | ﹤0.01% | 550 |
|
|
2023
Q2 | $13.9K | Buy |
58,672
+2,001
| +4% | +$630 | ﹤0.01% | 643 |
|
|
2023
Q1 | $22.1K | Sell |
56,671
-125
| -0.2% | -$40 | ﹤0.01% | 363 |
|
|
2022
Q4 | $9K | Buy |
56,796
+293
| +0.5% | +$74 | ﹤0.01% | 540 |
|
|
2022
Q3 | $11K | Buy |
56,503
+4,045
| +8% | +$1.04K | ﹤0.01% | 591 |
|
|
2022
Q2 | $27K | Buy |
52,458
+12,320
| +31% | +$5.08K | ﹤0.01% | 352 |
|
|
2022
Q1 | $24K | Buy |
+40,138
| New | +$25.4K | ﹤0.01% | 189 |
|
Other funds holding NRSNW
Clear Street's NRSNW Position: Q2 2026 in Review
Clear Street reduced its NeuroSense Therapeutics Warrant (NRSNW) stake by 0.47% in Q2 2026, selling an estimated $43 and leaving 63,085 shares worth $3.97K. The position accounts for ﹤0.01% of the portfolio, ranked #1280.
Clear Street first reported a position in NRSNW in Q1 2022 and has held it in 18 quarters since. The position peaked at $40.4K in Q2 2025. 3 funds tracked by Wall St. Rank hold NRSNW as of Q2 2026.
- Clear Street held 63,085 shares of NeuroSense Therapeutics Warrant worth $3.97K as of Q2 2026.
- Clear Street sold 300 NeuroSense Therapeutics Warrant shares in Q2 2026, an estimated $43.
- NeuroSense Therapeutics Warrant made up ﹤0.01% of Clear Street's portfolio in Q2 2026, its #1280 holding.
- Clear Street first reported a position in NeuroSense Therapeutics Warrant in Q1 2022 and has held it in 18 quarters since.
- Clear Street's NeuroSense Therapeutics Warrant position peaked at $40.4K in Q2 2025.
- 3 funds tracked by Wall St. Rank held NeuroSense Therapeutics Warrant as of Q2 2026.
Based on Clear Street's 13F filing for Q2 2026, filed 12 Aug 2026.